Abstract:Here, a cancer‐cell‐membrane‐camouflaged biocompatible platform (GA‐Fe@CMRALi liposome) is constructed to inhibit osteosarcoma efficiently by combining distinct differentiation and ferroptosis therapies through magnified reactive oxygen species‐triggered ferroptosis and apoptosis with homologous target capability to tumor sites. The combinational approach exhibits favorable therapeutic efficacy against osteosarcoma in vitro and in vivo. Notably, mRNA sequencing is utilized to disclose the potential mechanisms. Osteosarcoma (OS) is the most frequent osseous neoplasm among young people aged 10–20. Currently, the leading treatment for osteosarcoma is a combination of surgery and chemotherapy. However, the mortality remains high due to chemoresistance, metastasis, and recurrence, attributing to the existence of cancer stem cells (CSCs) as reported. To target CSCs, differentiation therapy attracts increasing attention, inducing CSCs to bulk tumor cells with elevated reactive oxygen species (ROS) levels and less chemoresistance. Moreover, increasing studies have implied that ferroptosis is a promising approach to eliminating cancer cells through eliciting oxidative damage and subsequent apoptosis, effectively bypassing chemoresistance. Here, a cancer‐cell‐membrane‐decorated biocompatible formulation (GA‐Fe@CMRALi liposome) is constructed to combat OS efficiently by combining distinct differentiation and ferroptosis therapies through magnified ROS‐triggered ferroptosis and apoptosis with homologous target capability to tumor sites. The combinational approach exhibited favorable therapeutic efficacy against OS in vitro and in vivo. Impressively, the potential mechanisms are revealed by mRNA sequencing. This study provides a tactical design and typical paradigm of the synergized differentiation and ferroptosis therapies to combat heterogeneous OS.

Ferroptosis defense mechanisms: The future and hope for treating osteosarcoma

Novel Therapeutic Savior for Osteosarcoma: The Endorsement of Ferroptosis

A Promising Future of Ferroptosis in Tumor Therapy

Targeting ferroptosis in osteosarcoma

Ferroptosis in Cancer Treatment: Another Way to Rome

Recent research progress based on ferroptosis-related signaling pathways and the tumor microenvironment on it effects

Advances in ferroptosis of cancer therapy

Ferroptosis in cancer therapy: a novel approach to reversing drug resistance

Harnessing ferroptosis for enhanced sarcoma treatment: mechanisms, progress and prospects

Insights Into Ferroptosis, a Novel Target for the Therapy of Cancer

Exploring Ferroptosis-Inducing Therapies for Cancer Treatment: Challenges and Opportunities

Amplified Ferroptosis and Apoptosis Facilitated by Differentiation Therapy Efficiently Suppress the Progression of Osteosarcoma

Advancing the frontiers of colorectal cancer treatment: harnessing ferroptosis regulation

Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges

Ferroptosis-Inducing Nanomedicine for Cancer Therapy

Ferroptosis and its emerging role in tumor

Advance on combination therapy strategies based on biomedical nanotechnology induced ferroptosis for cancer therapeutics

Emerging Therapeutic Approaches Targeting Ferroptosis in Cancer: Focus on Immunotherapy and Nanotechnology

Nanotechnology-integrated Ferroptosis Inducers: A Sharp Sword against Tumor Drug Resistance

Oridonin-induced ferroptosis and apoptosis: a dual approach to suppress the growth of osteosarcoma cells

Ferroptosis in Ovarian Cancer: A Novel Therapeutic Strategy